Lastly, as CDK4/6 inhibitors in combination with ET are approved for use in first‐line HR+, HER2− advanced breast cancer, some may question the applicability of our findings for a CDK4/6 inhibitor‐treated patient population. This evidence concerns the gene ERBB2 and breast carcinoma.